Neoepitopes arising from amino acid substitutions due to single nucleotide polymorphisms
are targets of T cell immune responses to cancer and are of significant interest in the …

TCR-T cell therapy represents a promising advancement in adoptive immunotherapy for
cancer treatment. Despite its potential, the development and preclinical testing of TCR-T …

The conformational landscapes of peptide/human leucocyte antigen (pHLA) protein
complexes encompassing tumor neoantigens provide a rationale for target selection …

The polymorphic nature and intrinsic instability of class I major histocompatibility complex
(MHC-I) and MHC-like molecules loaded with suboptimal peptides, metabolites, or …

Recognition of antigens by T cell receptors (TCRs) is a key component of adaptive immunity.
Understanding the structures of these TCR interactions provides major insights into immune …

Peptide-centric chimeric antigen receptors (PC-CARs) recognize oncoprotein epitopes
displayed by cell-surface human leukocyte antigens (HLAs) and offer a promising strategy …

Cellular immunity relies on the ability of a T-cell receptor (TCR) to recognize a peptide (p)
presented by a class I major histocompatibility complex (MHC) receptor on the surface of a …

Identifying highly specific T cell receptors (TCRs) or antibodies against epitopic peptides
presented by class I major histocompatibility complex (MHC I) proteins remains a bottleneck …

The binding of peptides to class-I Major Histocompability Complex (MHC) receptors and
their subsequent recognition downstream by T-cell receptors are crucial processes for most …

Background T cells form one of the key pillars of adaptive immunity. Using their surface
bound T cell antigen receptors (TCRs), these cells screen millions of antigens presented by …